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Abstract: Drug hypersensitivity reactions result from the activation of the immune system by drugs or 
their metabolites. The clinical presentations of drug hypersensitivity can range from relatively mild local 
manifestations to severe systemic syndromes that can be life-threatening. As in other allergic reactions, 
the causes are multifactorial as genetic, metabolic and concomitant factors may influence the occurrence 
of drug hypersensitivity. Formation of drug protein adducts is considered a key step in drug adverse 
reactions, and in particular in the immunological recognition in drug hypersensitivity reactions. 
Nevertheless, non-covalent interactions of drugs with receptors in immune cells or with MHC clefts 
and/or exposed peptides can also play an important role. In recent years, development of proteomic 
approaches has allowed the identification and characterization of the protein targets for modification by 
drugs in vivo and in vitro, the nature of peptides exposed on MHC molecules, the changes in protein 
levels induced by drug treatment, and the concomitant modifications induced by danger signals, thus 
providing insight into context factors. Nevertheless, given the complexity and multifactorial nature of 
drug hypersensitivity reactions, understanding the underlying mechanisms also requires the integration of 
knowledge from genomic, metabolomic and clinical studies.  
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1. INTRODUCTION 
Drug-induced activation of the immune system leads to hypersensitivity reactions that compromise 
therapeutic opportunities and may entail great severity, threatening the life of the patient or resulting in 
life-lasting sequelae. The clinical entities arising from drug hypersensitivity can be very varied. The 
presentations can range from contact dermatitis, urticaria, and angioedema, to severe anaphylaxis or the 
toxic epidermal necrolysis occurring in the Stevens–Johnson syndrome, among others. 
Many factors contribute to the ability of drugs to induce hypersensitivity reactions. Besides drug 
reactivity, genetic factors from the patient, factors affecting drug absorption and metabolism, as well as 
concomitant factors need to be taken into account. 
From a general perspective, it is necessary that several elements concur for activation of the immune 
system: an antigen that is processed and presented by antigen presenting cells (APC) to T-cells via MHC 
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molecules, a T cell repertoire able to recognize this antigen and co-stimulatory signals or a regulatory 
response [1]. The interactions of drugs with proteins are critical for the induction of hypersensitivity 
responses. There is still controversy regarding the need of covalent protein modification by drugs or their 
metabolites (haptenation), the minimum size of immunogenic structures or the requirement of a carrier for 
small molecules in order to activate the immune system. Nonetheless, protein-drug adduct formation is 
considered an important factor in hypersensitivity reactions in many cases. Haptenation can have 
consequences similar to that of protein modification by endogenous electrophiles [2]. It can induce severe 
alterations of protein structure and/or function, including protein unfolding, cross-linking and formation 
of aggregates. These alterations can affect cellular functions and compromise the capacity of cells to 
degrade damaged proteins leading to cytotoxicity and generation of danger signals or damage associated 
molecular patterns (DAMPS) [3]. An important consequence of protein modification may be also the 
generation of an unfolded protein response, which can have deleterious consequences for cells. These 
effects can contribute to the coactivation of the immune system.  
In addition, protein modification can result in increased immunogenicity, since modified proteins can be 
recognized as “non-self” proteins or neoantigens. In certain autoimmune diseases, proteins suffer 
posttranslational modifications that render them immunogenic. For instance, citrullinated peptides from 
several endogenous proteins, including extracellular and intracellular proteins like vimentin, alpha-
enolase and histones, act as antigens to which auto-antibodies are detected in several inflammatory 
diseases, like arthritis [4, 5]. Moreover, carbamylated and acetylated vimentin are also recognized by 
autoantibodies from patients [6]. Indeed, it has been shown that some of these modified peptides can bind 
certain HLA alleles [7, 8]. Therefore, the possibility exists that drug-protein or peptide adducts can act as 
neoepitopes. 
Insight into the mechanisms of drug hypersensitivity in order to achieve a better prevention, diagnosis and 
treatment requires multidisciplinary approaches. Proteomic techniques can provide information on the 
drug-adducts formed, which in some cases may be critical for activation of the immune system. 
Moreover, identification of adducts formed in vitro or in patients’ sera can provide novel antigenic 
determinants for diagnosis, and, in the mid-term perhaps for desensitization strategies. In many cases, in 
vitro tests for diagnosis are necessary due to the risk of performing provocation tests. In vitro tests 
employ complexes of the drugs of interest with serum albumin or with electrophilic amino acids, 
synthetic polymers or nanostructures to probe the antibodies present in the patients’ sera or to perform 
cellular activation assays [9, 10]. Nevertheless, these structures may not represent the endogenous 
antigens and result in false negatives or low sensitivity. Identification of the “actual” adducts formed in 
patients allows using more relevant antigens for in vitro tests  and may also provide information on the 
processes underlying cross-reactivity or selectivity of drug hypersensitivity, which, in some cases relate to 
the structure of the drug. 
In recent years, development of proteomic and mass spectrometry (MS) techniques is yielding a great 
wealth of information on protein adduction by endogenous and exogenous reactive compounds. 
Identification of covalent drug-protein adducts can use label-dependent and label-free techniques. In the 
first case, the drug is labeled with a fluorescent or a biotin moiety [11]. These approaches enable 
detection of adducts by the appropriate techniques generally after one-dimensional (1D) or two-
dimensional (2D) electrophoresis and direct detection in the gel or after transfer to a membrane (blot) 
(Fig. 1). Whereas these techniques are useful to visualize adducts and to identify the modified proteins, 
for instance by peptide mass fingerprinting, they usually do not provide information on the site of 
modification and/or structure of the adducts. Other labeling strategies include “click technology” that uses 
azido and alkenyl derivatives of electrophilic compounds for subsequent adduct derivatization and 
detection [12, 13], or synthesis of isotopically labeled derivatives recognizable by MS. In cellular and in 
vitro model systems, drugs or their metabolites can be labeled to facilitate the detection, enrichment 
and/or identification of adducts. However, these techniques cannot be used to study adduct formation in 
patients. 
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The development of MS strategies of high resolution and sensitivity allows addressing the study of adduct 
formation in patients, which necessarily has to be performed by means of label-free approaches. In the 
label-free techniques, protein adducts can be detected by specific antibodies against the drug moiety when 
available, or by MS, identifying the mass increment corresponding to the adduct or to the specific ions 
resulting from its fragmentation in the spectrometer under the different dissociation conditions (diagnostic 
fragments). Moreover, MS/MS techniques can provide information on the precise residues that are 
modified on proteins and on the structure of the modifying moieties. In addition, when possible, 
derivatization of the adduct can provide additional means of detection. Highly specialized equipment and 
protocols are required for the detailed structural characterization of adducts by high resolution MS, 
whereas the requirements for adduct detection by immunological or label-dependent approaches can be 
met by most biochemistry laboratories. 
It is important to consider that knowledge of drug metabolism may be critical for identification of drug-
protein adducts since, often is not the parent drug but its metabolites the ones responsible for protein 
modification and toxicity. Acetaminophen (paracetamol), metamizol, nevirapine, and celecoxib, among 
others, are examples of this [14]. Therefore, it is key to have a good knowledge of metabolic 
transformations that can lead to chemically reactive drug metabolites. To achieve this knowledge is 
necessary to develop analytical strategies to identify these metabolites and their potential [15]. Thus, 
proteomic studies on drug hypersensitivity are strongly dependent on advances on drug metabolomics.  
Besides drug metabolism, the cellular capacity for exporting drugs or drug conjugates will influence their 
accumulation. These processes depend also on genetic factors from the patient. In this sense, individual 
susceptibility can be correlated with genomic studies, and in fact, associations of genetic variants with the 
risk of developing drug hypersensitivity have been found for many drugs [16-18].  
In addition, access to the synthetic or purified drug metabolites and in vitro generation of the drug- or 
metabolite-protein adduct can provide valuable information about the immunogenic structures since, in 
some cases the adducts formed are not stable and can suffer transformations difficult to predict, giving 
rise to structures that may be responsible for the hypersensitivity reaction. Therefore, the contributions of 
chemical synthesis and analytical chemistry to this field are critical. 
On the other hand, quantitative proteomics, as in the liquid chromatography-MS-based approaches 
SILAC (stable isotope labeling amino acids in cell culture) and iTRAQ (isobaric tags for relative and 
absolute quantitation) provides information on the changes in protein levels that may occur upon 
exposure to a drug in a tissue or in a cellular experimental system. In addition, 2D-electrophoresis-based 
methodologies, like DIGE (differential in-gel electrophoresis), can be used with quantitative purposes 
[19, 20]. The proteomic characterization of tissues can yield information to unveil or confirm pathogenic 
mechanisms. For instance, proteomic characterization of serum and blister liquid in drug-induced toxic 
epidermal necrolysis supported the involvement of macrophages and keratinocytes in the pathogenesis of 
this reaction [21]. In this regard, as for many diseases, proteomics can also be useful in the identification 
of biomarkers for predisposition to drug or chemical hypersensitivity [22]. Proteomic studies on 
identification of potential biomarkers have been carried out in animal models, i.e., in mice subjected to 
hapten challenge [23], and in patients suffering from various types of adverse drug reactions [24]. The 
importance of proteomics in several aspects of drug toxicity has been the subject of a comprehensive 
review covering the characterization of the proteome and adductome [25].  
In addition, proteomic studies can provide valuable information on the context factors contributing to 
hypersensitivity reactions. Among these, the metabolic and redox state of cells are important factors that 
can influence the extent of the formation of drug-protein adducts, as well as their nature [26], as it will be 
detailed below. Therefore, redox proteomics and proteomics of electrophilic modifications combined with 
studies on drug exposure may provide valuable information for the understanding of the haptenation 
process and its involvement in drug hypersensitivity. 
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Nevertheless, in spite of extraordinary advances in the knowledge of the interactions of drugs or their 
metabolites with proteins in recent years, the challenge remains to understand, and therefore predict, 
when the formation of such complexes, which also occur in healthy subjects, is going to trigger an 
allergic reaction. For this, a thorough understanding of the concurrent individual circumstances is 
necessary. In summary, multiple disciplines should contribute to untangle the complex mechanisms for 
drug hypersensitivity which are subject to individual and context factors as well as to factors depending 
on each drug. In this article, we discuss general aspects of drug hypersensitivity, paying special attention 
to findings obtained through proteomic approaches on both drug-protein interactions and on context 
factors such as redox status and inflammation. However, given the high number of excellent works in this 
topic, some of them may not be reflected in the present review. 
2. PROTEOMICS IN THE CHARACTERIZATION OF CONTEXT FACTORS FOR DRUG 
HYPERSENSITIVITY REACTIONS 
2.1. Redox proteomics 
Situations associated with oxidative stress are known to act as cofactors for allergic reactions of diverse 
nature in the clinic. Moreover, the relationship between oxidative stress and adduct formation, as well as 
its importance in the generation of danger signals are known. However, the precise connections have not 
been elucidated. 
Redox status is determined by the action of low molecular weight agents and macromolecules. 
Glutathione (GSH) is the most important low molecular weight thiol determining the redox status of cells. 
GSH can modulate the redox balance by acting as a reduction equivalent in cells and prevent the 
oxidation of proteins’ sulfhydryl groups. Additionally, GSH is involved in the detoxification of 
xenobiotics through its conjugation that can be catalyzed by detoxifying enzymes such as GSTP1-1, or 
occur non-enzymatically [25, 27]. GSH-drug conjugates are finally detoxified through their export by 
MDR transporters that can be themselves sensitive to redox or electrophilic modifications [28]. 
Among the macromolecules involved in the control of redox status are enzymes that regulate the levels of 
GSH, like γ-glutamyl-cysteine synthase, the balance between other redox-active cofactors, like 
NAD(P)/NAD(P)H or the oxidative state of the cellular proteins. Enzymes such as aldose reductase 
(AKR1B1), GSTP1-1 and thioredoxin can modulate the cellular redox state. These redox-regulating 
proteins have been implicated in the modulation of certain hypersensitivity reactions, such as asthma [29, 
30]. Proteomics has rendered critical information on the regulation of cellular redox status and on protein 
modifications [31]. Among these modifications the various forms of cysteine oxidation can play 
regulatory roles and impact in drug metabolism and disposition. Conversely, certain drugs can regulate 
the expression of redox-regulating proteins, which in turn, can be modified by drug addition, with 
consequences on the redox status. Therefore, a complex regulation exists between redox regulation and 
drug adduction. 
Interestingly, adduct formation by sulfamethoxazole in antigen presenting cells has been shown to 
increase under conditions of oxidative stress [32]. Indirect evidence based on the use of the sulfenic acid 
probe dimedone, indicates that this effect may be due, at least part, to the improvement of binding of the 
drug to oxidized proteins, particularly to cysteines oxidized to sulfenic acid [32].  
In plasma, glutathione levels are very low and the main free thiol-containing molecule is albumin, which 
is the main antioxidant and plays an important role in plasma redox status. Albumin possesses 35 cysteine 
residues, all of which, except Cys34 are involved in the formation of structural disulfide bonds. Cys34 is 
responsible for the antioxidant action of albumin and can scavenge several electrophilic and oxidant 
compounds [33, 34]. Moreover, the free thiol content of albumin is reduced in pathophysiological 
conditions associated with oxidative stress, such as chronic renal failure, coronary heart disease, or during 
exercise. Several oxidation forms of Cys34 have been identified, including mixed disulfides and 
irreversible oxidations like sulfonic acid [34]. Interestingly, Cys34 is also the target for covalent 
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modification by various drugs involved in hypersensitivity reactions, including abacavir, nevirapine, and 
gold antiathritic agents [35-37]. Therefore, the redox status will affect the availability of Cys34 for 
modification by these drugs. 
2.2. Interactions with inflammation  
It is obvious that drug hypersensitivity reactions, except when elicited by provocation tests, occur in the 
context of therapeutic regimes, therefore coincident with some pathological condition. Very often the 
diseases treated involve some kind of metabolic alteration, inflammation and/or infection. Therefore, the 
risk for concomitant factors and generation of danger signals is increased. Proteomic techniques can play 
an important role in the characterization of the context factors that may contribute to the hypersensitivity 
reaction. 
Associated pathogenic conditions such as infection or inflammation can have important consequences for 
drug adduct formation by various mechanisms, including the generation of electrophilic reactive 
mediators that also target proteins and may compete or cooperate with drug-induced modifications. As 
reflected in Figure 2, in a situation of inflammation, both drugs and endogenous electrophilic mediators 
coexist. Modification of proteins by electrophilic compounds can induce protein unfolding, thus exposing 
novel sites for drug adduction. In addition, as outlined above, in specific cases, formation of drug adducts 
may be more efficient on oxidized proteins [38]. Certain proteins are particularly prone to modification 
by endogenous or exogenous electrophiles. That is the case of GSTP1-1, which is the target for 
modification by cyclopentenone prostaglandins, ethacrynic acid, and chlorambucil [39-41]. Some of these 
reactive compounds can compete for the same sites on the protein [41]. Therefore, multiple combinations 
of modified species can potentially rise by the coexistence of drug treatment, oxidative stress and reactive 
inflammatory mediators. Electrophilic mediators can also act by indirect mechanisms including the 
regulation of the expression and/or activity of detoxifying enzymes, and affecting the expression or 
activity of multidrug resistance proteins [28].  
System approaches have been used to characterize the modification of proteins by endogenous or 
exogenous electrophiles and their functional consequences. In some of these studies, endogenous lipid 
electrophiles, typically generated under inflammatory conditions, have been used as models due to their 
broad reactivity towards nucleophiles and the availability of detection methods [13, 42].  
Also, coexistence of inflammatory conditions may potentiate the toxic effects of drugs or reduce the 
threshold at which they can induce adverse effects. For instance, acetaminophen has been shown to 
increase the production of inflammatory cytokines in a macrophage cell line, an effect that is potentiated 
by bacterial lipopolysaccharide and may be related to an increased bioactivation of acetaminophen by 
cytochromes and cyclooxygenases [43]. 
We have recently reviewed the methodology and challenges of proteomic analysis of modifications by 
various inflammatory mediators, which in many cases may be applicable to drug-protein interactions [42, 
44]. Nonetheless, combinations of approaches will be needed to fully characterize the protein 
modifications generated in pathophysiological conditions under therapeutic regimes. 
3. PROTEOMICS IN THE CHARACTERIZATION OF DRUG-PROTEIN INTERACTIONS 
3.1. Non-covalent drug-protein interactions 
Although drug hypersensitivity reactions are most often attributed to covalent interactions of drugs with 
proteins, they can also be due to non-covalent interactions. For instance, interaction of drugs with 
peptides exposed on MHC can activate the immune system or induce peptide conformations that are more 
immunogenic, in what is known as “the pharmacological interaction concept” [45]. Quantitative high 
throughput MS-based approaches have allowed to characterized the endogenous peptides presented by 
MHC class I molecules, or immunopeptidome [46]. Interestingly, altering cellular metabolism, influences 
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the immunopeptidome, which provides a link between metabolic context factors and the immune 
response [46]. 
Thus, proteomic approaches can provide information on the nature of peptides exposed by various cell 
types treated with drugs, and on the quantitative differences between peptides exposed by control and 
drug-treated cells. 
An interesting example of non-covalent interaction is that of abacavir, a nucleoside analog used as 
inhibitor of viral reverse transcriptase that has been the subject of study of many excellent works in this 
field. Induction of drug hypersensitivity by abacavir seems to be directly related to the expression of the 
HLA-B*57:01 type. Proteomic experiments have explored the patterns of peptides associated to HLA-
B*57:01 in cellular assays. It was shown that abacavir but not other drugs enhanced the binding of a self-
peptide to HLA-B*57:01. Moreover, the peptides exposed on HLA-B*57:01 were different in control and 
in abacavir-treated B-cells. Thus, abacavir-induced autoimmunity could be due to alteration in the 
quantity and/or quality of self-peptide loading into HLA-B*57:01, or related to potential alterations in the 
peptide binding cleft or in the peptide-loading complex, finally generating a panel of neo-antigen peptides 
[47]. In addition, it has been reported that abacavir can activate T-cells both through a direct interaction 
with MHC molecules at the APC surface, and through interaction with intracellular MHC [48], which 
elicits peptide exposure as a consequence of abacavir treatment.  
iTRAQ technology and LC-MS platform approaches have been used to accomplish the identification of 
MHC class I-associated peptide antigens in cisplatin-resistant ovarian cancer cells, which may be 
recognized by specific cytotoxic T-lymphocytes [49]. Therefore, from the above examples the possibility 
emerges that drug hypersensitivity is favored by drug-induced presentation of a different repertoire of 
peptides or by quantitative differences in the peptides exposed.  
In addition, numerous proteins including HSA, GSTP1-1, nuclear and membrane receptors can bind drugs 
through non-covalent interactions [50, 51]. MS approaches exist that allow detection of non-covalent drug 
protein complexes. In the case of the enzyme aldose reductase, a complex with non-electrophilic 
prostaglandins that is reversed under denaturing conditions has been observed by MALDI-TOF MS [52]. 
This type of interaction can affect the function and conformation of the proteins and/or shield specific 
sites for modification by other drugs or endogenous mediators. For instance, nuclear receptors of the 
PPAR family are able to accommodate several types of drugs in their binding sites. In fact, many of these 
drugs can act as agonists for these receptors [53]. However, the presence of drugs at the binding site can 
hamper activation by endogenous ligands and/or shield reactive residues present in this region from 
modification by electrophilic compounds [54]. Given the importance of many of these proteins in the 
inflammatory response, these interactions could alter the response of immune cells.  Nevertheless, the 
direct implication of non-covalent drug-protein complexes, such as those occurring on albumin, in 
allergic responses to drugs is not established. 
3.2. Drug-protein adduct formation 
The development of MS strategies is being critical for the characterization of drug-protein adducts, the 
structure of which is difficult to predict, either because is not the drug, but a metabolite, the molecule 
responsible for protein adduction or because the adduct can suffer additional chemical transformations 
(see Figure 3 for the structures and some drugs/metabolites and their adducts). In addition, detection and 
quantitation of drug-protein adducts are important for the of drug toxicity through non-immunological 
mechanisms [25]. 
Acetaminophen can be bioactivated by cytochromes P450 2E1 and also P4503A4 and P450 1A2-
catalyzed oxidations to the electrophilic intermediate N-acetyl-p-benzoquinoneimine (NAPQI). This 
metabolite can be detoxified by conjugation to GSH; however, when paracetamol doses are very high, it 
can accumulate, deplete cellular stores of GSH and form adducts with cysteine residues in proteins [55]. 
These adducts have been extensively studied, because overdose of this drug is the most frequent cause of 
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acute liver failure in developed countries. Liver toxicity correlates with the levels of protein adducts 
formed, and quantitative methods have been developed to assess the extent of adduct formation as an 
index to confirm diagnosis, predict toxicity and/or establish prognosis during therapeutic regimes or upon 
intoxication with this drug [56, 57]. Nevertheless, the mechanisms of liver toxicity by acetaminophen do 
not depend in principle from immunological mechanisms, but are related to the perturbation of protein 
function, redox disbalance and intense oxidative stress damage. These processes have been studied in 
detail in animal models [58]. Nevertheless, subsequently, release of DAMPs and mediators from cell 
necrosis can trigger an inflammatory reaction, which interestingly, has been proposed to be beneficial 
because it helps to remove damaged cells and promotes tissue repair [59]. 
In the case of abacavir, in addition to the non-covalent interactions with HLA-B*57:01 discussed above, 
covalent adducts with proteins in vitro and in patients have also been detected. In particular, an adduct of 
abacavir aldehyde with hemoglobin was observed in HIV patients receiving this drug [60]. This prompted 
studies on the formation of adducts between this compound and other proteins. In particular, several 
adducts of abacavir and HSA have been detected in patients, which involve Cys34 alone or forming a 
crosslinking product with Gln33, and an adduct at His146 [35]. These are dependent on the oxidative 
transformation of abacavir giving rise to a reactive aldehyde. Moreover, several additional adducts have 
been observed upon incubation of the synthetic α/β-unsaturated aldehyde with proteins in vitro [35]. 
Thus, this reactive metabolite of abacavir could be hypothetically involved in eliciting allergic reactions.  
These examples illustrate the fact that the structures of the adducts formed upon drug treatment are not 
obvious. For this reason, assays with single amino acids or model peptides have been carried out and 
subjected to different analytical procedures to study their characteristic ion patterns. In the case of the 
chemotherapeutic agent melphalan, its reactivity towards single amino acids has been recently studied 
[61]. Characterization of adducts with synthetic tryptic peptides from HSA has been critical for the 
subsequent identification of the modification sites by amoxicillin in ex vivo samples [62].  Other 
synthetic peptides and proteins containing nucleophilic residues have been used as models to explore the 
reactivity of drugs. The binding capacity of a nitrosylated form of sulfamethoxazole has been analyzed by 
in vitro incubations with the synthetic peptide “DS3”, observing that this compound reacts mainly with 
the cysteine residue [63]. The detoxifying protein GSTP1-1, which contains several reactive cysteines, 
has been frequently used as a model for exploring adduct formation in vitro and in cells [41, 64], although 
the direct involvement of drug-modified GSTP1-1 in hypersensitivity reactions is not established. In 
particular, GSTP1-1 has been shown to form adducts with diclofenac and its metabolite 5’-
hydroxydiclofenac at cys14 and 47 [65] and with the toxic reactive metabolite of acetaminophen N-
acetyl-p-benzoquinoneimine at cys47 [64]. In this last work, a modified iTRAQ method is described to 
allow a fine quantitative detection of adduct formation that can be correlated with the functional outcome. 
Moreover, some drugs, like chlorambucil, can induce intermolecular crosslinking of GSTP1-1 monomers, 
which can be observed by SDS-PAGE [41]. In vitro studies using HSA and GST as models have also 
served to characterize adducts formed by the bioactivated metabolite of the reverse transcriptase inhibitor 
nevirapine, previous to the identification of adducts in samples from patients receiving this therapy [36]. 
Nevertheless, as stated above, formation of adducts may be necessary but not sufficient to trigger an 
allergic reactions since it occurs also in non-allergic patients. 
Interestingly, in the case of triflusal, the active metabolite produced, 2-hydroxy-4-trifluoromethylbenzoic 
acid (HTB), is able to form adducts with proteins in an irradiation-dependent manner, for which it has 
been proposed to be involved in the induction of photosensitivity [66]. Single amino acids as well as HSA 
have been used to study the photoadduct, which in HSA appears to be located at site I. Moreover, the 
photoadduct can be produced both upon multi-lamp photoreactor and sunlight irradiation. However, it is 
not currently known whether this particular adduct may be involved in triggering the allergic reactions 
produced by this drug. Recently, the small protein ubiquitin has been used as a model for the 
characterization of HTB adducts by MS. A single adduct was observed after sun-light irradiation of 
mixtures of ubiquitin and HTB. However, addition does not appear to occur at a specific residue but it can 
affect any of the lysine residues in ubiquitin (Nuin et al., unpublished data). 
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Acyl glucuronides are electrophilic drug metabolites that may form glycation adducts with proteins either 
by direct acylation or by Schiff base formation [67]. Diclofenac acyl glucuronide is highly reactive and 
can form adducts with HSA both in vitro and in patients. Exhaustive analysis of the reaction of this 
metabolite with HSA in vitro has allowed the identification of the adducts present in subjects without 
drug hypersensitivity [68]. This has shown a complex and varied pattern of modification of albumin in the 
different subjects, involving diverse lysine residues, and highlighted the fact that modification of albumin 
is not sufficient to induce a hypersensitivity reaction. 
A proteomic approach has been used to identify covalent adducts of an active metabolite of raloxifene, an 
oral selective estrogen modulator, and cytochrome P450 3A4 [69]. Using a reconstituted cytochrome 
P450 3A4 system for incubation with the reactive metabolite, followed by trypsin digestion and nano-
LC/linear ion trap-Fourier transform ion cyclotron resonance (FTICR) MS, an adduct was identified 
likely involving the nucleophilic hydroxyl group of Tyr75 of cytochrome P450 3A4.  
Approaches with model peptides and proteins can later be integrated in cellular assays to explore the 
immunogenic potential of the modified structures. For instance, a model peptide as well as HSA, were 
used as acceptors for the human skin sensitizer 2,4-dinitrobenzenesulfonic acid (DNBS) and 2,4-
dinitrochlorobenzene (DNCB). After demonstrating the chemical modification, cells were exposed to 
these chemicals and the formation of adducts with intracellular proteins were evidenced by 2D-PAGE and 
immunological detection with anti-DNP antibodies. Subsequently, chemically-modified cells were used 
in functional assays of activation of T-lymphocytes [70]. 
Blood proteins have received a great deal of attention in studies on drug hypersensitivity, and some of the 
adducts described for HSA appear summarized in Table 1.  
Nevertheless, intracellular proteins are also the targets for adduct formation and therefore, could be 
involved in triggering allergic reactions. However, there are fewer studies exploring nature of the 
intracellular adducted proteins. In a study by Sanderson et al., binding of nitroso-sulfamethoxazole to the 
surface of dendritic cells as well as intracellular adducts of both sulfamethoxazole and nitroso-
sulfamethoxazole were detected using immunological detection with an antibody against the drug [71]. 
More recently, the irreversible binding of nitroso-sulfamethoxazole and sulfametoxasole to APC has been 
reported and these cells were able to activate nitroso-sulfamethoxazole-specific T-cells. Thus, this work 
shows that metabolic activation of sulfamethoxazole by APC can generate antigenic determinants 
recognized by T cells. In addition, myeloperoxidase is identified by MS as one of the potential targets for 
modification by nitroso-sulfamethoxazole [72]. In a recent study, we have obtained insight into the 
identity of the cellular targets for modification by beta-lactam antibiotics, which will be discussed below. 
4. PROTEOMICS IN THE ELUCIDATION OF THE MECHANISMS INVOLVED IN 
HYPERSENSITIVITY TOWARDS BETA-LACTAM ANTIBIOTICS 
Beta-lactam antibiotics are amongst the drugs most frequently inducing hypersensitivity reactions and 
they have been the subject of extensive study. The reactivity of beta-lactams antibiotics is well known. 
Generally, a protein nucleophile, most often the amino group of a lysine residue, attacks the beta-lactam 
ring producing its opening and the formation of an amide bond (Fig. 3). The high tension of the core 
structure of penicillins, a four member beta-lactam ring fused to the five-member thiazolidine ring, 
contributes to the readiness of this process [10]. Adducts formed by beta-lactams and amino acids or 
proteins have been exhaustively characterized. In addition, this property has been exploited for the 
generation of complexes between penicillins and butylamine or polylysine to be used in diagnostic 
procedures. Therefore, adducts formed are stable and can be analyzed by various methods, including MS 
and NMR.  
Early studies on the formation of protein adducts by beta-lactam antibiotics employed trypsin or 
cyanogen bromide digestion of penicillin-modified albumin from patients, followed by HPLC analysis 
and sequencing by Edman degradation [73], whereas benzylpenicilloyl content was determined in the 
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different fractions by enzyme immunoassay. In this study, Lys190, 195, 199 and Ser193 were identified 
as residues containing adducted benzylpenicilloyl [74]. Since then, the development of proteomic and MS 
methods has allowed the assessment the haptenation of HSA by various beta-lactams, both in vitro and in 
the serum of patients, and in different pathophysiological conditions.  
Regarding the identification and characterization of adducts of several beta-lactams, Prof. K. Park and co-
workers have performed excellent and exhaustive studies on the detection of drug-protein adducts in 
general and adducts of beta-lactam antibiotics, in particular, both in vitro and in ex vivo samples from 
patients. Adducts of flucloxacillin and its metabolite 5-hydroxymethyl flucloxacillin were detected in 
HSA from the serum of patients treated with this drug [75]. This was achieved by several 
chromatographic steps followed by MS, and revealed Lys190 and Lys212 as the residues more frequently 
modified. In another study using three different beta-lactams, namely, piperacillin, meropenem, and 
aztreonam, Lys190 was found to be modified by the three of them [76]. Haptenic structures generated by 
piperacillin involving Lys190, 452 and 541 constituted functional antigenic determinants for T-cells [77]. 
Several HSA residues emerge from these studies as the most frequently modified by the various 
antibiotics studied, in particular lysines 190, 195 and 199; however notable variations exist in the patterns 
of modification (reviewed in [10]). The reasons for the differences observed upon in vitro modification of 
HSA probably reside in structural differences between the beta-lactam molecules or the incubation 
conditions employed. The differences observed in samples from patients likely arise from variations in 
the therapeutic regimes, including dosage and administration route or from the presence of concomitant 
treatments or pathological conditions. 
The development of immunological tools has also played an important role in the detection of beta-
lactam-protein adducts in vivo or in experimental systems, and in the design of diagnostic procedures. In 
earlier studies, HSA and transferrin from the serum of ampicillin-treated patients were identified as 
proteins modified by this antibiotic by 2D-electrophoresis and western blot with an anti-penicilloyl 
antibody [78]. Mayorga et al., [79] developed a series of monoclonal antibodies against amoxicillin that 
were directed or reactive towards different parts of the molecule. Among them, antibody AO3.2, 
recognized the lateral chain, the structure of which differs in the various penicillins, plus part of the 
nuclear region and antibody AO19.1 recognized the lateral chain plus the open beta-lactam ring of the 
molecule. These antibodies were effective at detecting amoxicillin-protein adducts in western blot [62]. In 
addition, a different anti-amoxicillin antibody has been employed in immunohistochemistry studies 
showing the distribution of the antibiotic in various tissues in rats [80] and its correlation with the 
presence of penicillin transporters at these sites. An antibody against a rabbit serum albumin-
flucloxacillin conjugate has also been developed that recognizes flucloxacillin-adducted proteins in liver 
extracts from flucloxacillin-treated rats [81]. Moreover, there are commercial antibodies against penicillin 
that can recognize amoxicillin-protein adducts, although with lower sensitivity than benzyl-penicillin 
adducts [62]. 
In a recent work, we employed a combination of MS approaches and immunological detection using 
several monoclonal antibodies to identify novel serum targets for modification by amoxicillin. This 
allowed detection of several targets, including HSA, transferrin and light and heavy chains of 
immunoglobulins, some of which were previously unnoticed [62]. In addition, the modification of HSA 
was addressed by high resolution MS techniques using both top-down and bottom-up approaches. We 
firstly evaluated the reactivity of amoxicillin towards nucleophilic residues such as histidine, lysine and 
cysteine, by measuring the covalent adduction of amoxicillin towards synthetic HSA fragment peptides 
containing Lys199, His146 and Cys34. The relative abundances of the adduct-bearing with respect to the 
native peptides were found to be different: the Lys199-containing peptide was the most reactive (12%) 
followed by the His146-containing peptide (3%) while Cys34 was modified in a negligible amount. The 
ability of amoxicillin to form covalent and non-covalent adducts with HSA was then demonstrated by 
directly infusing the amoxicillin:HSA reaction mixture into the ESI source. The characterization of these 
adducts has permitted to establish the stoichiometry of reaction as well as to identify the adducted moiety 
which, on the basis of the MW, was attributed to the amoxicilloyl residue. Identification of the HSA sites 
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covalently modified by the amoxicilloyl residue was then carried out by a bottom-up approach using 
trypsin and trypsin plus chymotrypsin for protein digestion. When purified HSA was incubated with 
amoxicillin (5 mg/ml), 6 lysine residues were found adducted, namely Lys190, 199, 351, 432, 541 and 
545. When amoxicillin was used at a 10-times lower concentration, only Lys190, 199 and 541 were found 
to be modified, thus suggesting their greater reactivity [62]. Molecular modeling studies were then 
performed in view to rationalizing the reactivity of the adducted lysine residues. We found that the 
adducted lysine residues are characterized either by a very low basicity which render them extremely 
reactive regardless of their accessibility (as in the case of Lys190 and Lys199), or by a significant 
accessibility which markedly facilitates their approach by amoxicillin (as seen for Lys351, Lys541 and 
Lys545). In general, molecular modelling studies have suggested that the marked reactivity of the 
targeted lysine residues is modulated not only by the residue accessibility, but also by the 
microenvironment around the lysine residue which can enhance the intrinsic reactivity of the lysine 
residues and contribute to the binding of amoxicillin through a sort of recognition process which can 
stably constrain amoxicillin in a pose conducive to adduct formation [62].  
The next step was to confirm the ability of amoxicillin to form covalent adducts with HSA in ex vivo 
samples from healthy subjects under oral amoxicillin administration (acute intake of 1 g every 8 h for 48 
h). To reach this goal, we used an analytical strategy based on targeted and untargeted MS approaches. 
Lys190 was identified as the only modification site of HSA in the ex vivo samples and the relative 
amount of the modified residue ranged from 1 to 2% (6−12 μM) at 24 and 48 h after the oral intake [82]. 
Again, the fact that the amoxicillin-HSA adduct is detected in healthy subjects illustrates again that 
adduct formation is a common phenomenon requiring other factors in order to elicit the allergic reaction. 
The avidin-biotin system is characterized by its high affinity interaction. Our group has extensively 
employed this system in the analysis of protein targets for various reactive electrophiles [83, 84]. 
Recently, we synthesized a biotinylated analog of amoxicillin for its use in in vitro model systems in 
order to detect amoxicillin targets with high sensitivity [11]. This analog incorporates a biotin moiety 
coupled to the amino group in the lateral chain of the molecule. Therefore, as expected, this impairs its 
recognition by monoclonal antibodies directed against the lateral chain. This lack of recognition allows 
observing the competition between amoxicillin and its biotinylated analog for binding to protein targets, 
both in vitro and in cells. Using this analog, the panel of serum proteins that can be modified by 
amoxicillin in vitro has been expanded, including haptoglobin, which could not be detected by 
immunological procedures [11]. These studies will provide novel candidates to be used in functional 
assays of activation of T-cells or other components of the immune system involved in the allergic 
reaction. Nevertheless, it should be taken into account that introduction of a bulky moiety into the 
molecule of amoxicillin, like the biotin moiety, could result in steric hindrances of its interaction with 
certain targets, for which is very important to confirm the results obtained with biotinylated amoxicillin in 
assays using the parent antibiotic. 
Most of the attention regarding adduct formation by beta-lactam antibiotics has been directed towards de 
characterization of serum proteins, mainly HSA, as a carrier protein for these drugs. Nevertheless, other 
possibilities can be considered. As discussed above, cell surface or intracellular proteins could also play a 
role in the activation of the immune system. However, studies addressing the identification and 
characterization of intracellular targets for the formation of drug-protein adducts are scarce. In a previous 
work we combined immunological techniques with the use of biotinylated amoxicillin to detect 
intracellular proteins modified by amoxicillin in several cell types showing that the patterns of modified 
proteins were cell-type-dependent [11]. Studies in cellular systems can also provide information on the 
fate of the adducts formed and help elucidate whether they are degraded by lysosomal or proteasomal 
pathways or directed towards specific cellular compartments. In a recent study, we have used a B-
lymphocyte cell line to detect, identify and follow the fate of intracellular amoxicillin-protein adducts. 
Remarkably, we have observed that amoxicillin covalently binds to a subset of proteins in cells, in a 
manner that does not depend on protein abundance [85]. Moreover, amoxicillin-protein adducts can be 
detected in the conditioned medium from cells, both in soluble form and in a vesicular fraction. A detailed 
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analysis of the generation of this extracellular vesicle fraction revealed that intracellularly haptenated 
proteins can be incorporated into exosomes and secreted in this fraction. We have shown that exosomes 
carrying haptenated proteins can be taken up by endothelial cells, which are APC [85], although, at 
present, the direct involvement of these vesicles in immune cell activation in response to drugs has not 
been demonstrated. We have observed that amoxicillin can also bind to isolated exosomes. Therefore, the 
possibility exists for amoxicillin and other drugs to haptenate protein components of exosomes already 
present in the circulation at the time of administration. These results constitute the first report of 
haptenated proteins in exosomes [85]. Exosomes act as vehicles of biologically active molecules, 
including small RNA, MHC molecules, tetraspanins, and signaling proteins, even between distant 
locations in the organism [86]. In the immune system, exosomes have been reported to contribute to T-
cell activation, dendritic cell maturation, antigen presentation and modulation of gene expression [87]. 
Given the importance of these extracellular vesicles in the activation of the immune system, these 
observations unveil novel possibilities for hapten formation and transport.   
CONCLUSIONS 
Development of proteomic approaches and high resolution MS techniques is providing extremely detailed 
information on the formation of drug-protein adducts with great sensitivity. This constitutes highly 
valuable information for elucidating the mechanisms of drug allergy. Nevertheless, integration of 
knowledge from other fields, including genomics and metabolomics, is required to achieve this goal. In 
addition, although knowledge of protein-drug adducts will be very important, the contribution of context 
factors and danger signals to the immune response cannot be overlooked, Cross-talk with redox and 
inflammatory pathways can determine the extent and nature of the adducts or the modified species 
formed. There are proteins particularly reactive that have been shown to be the target for various drugs, 
redox and electrophilic modifications. Under multidrug regimes they could potentially be modified by 
several drugs at the same time. Among these proteins are HSA in the circulation and GSTP1-1 in cells. 
Indeed, several protein targets could be considered as platforms for modification by drugs and 
endogenous mediators that could modify different sites or even compete for the same site(s) on the 
protein. Assessing the modifications of these proteins in experimental systems and in patients is providing 
valuable information on the nature of drug protein interactions and their involvement in hypersensitivity 
reactions. 
In summary, multidisciplinary approaches are required to address the pathogenesis of drug 
hypersensitivity reactions, in the same way that treatment of drug allergy and its sometimes life-lasting 
consequences requires interdisciplinary clinical care. 
LIST OF ABBREVIATIONS 
AKR, aldose keto-reductase 
APC, antigen presenting cell 
GSH, glutathione 
GST, glutathione transferase 
HSA, human serum albumin 
HTB, 2-hydroxy-4-trifluoromethylbenzoic acid 
iTRAQ, isobaric tags for relative and absolute quantitation 
LC, liquid chromatography 
MHC, molecular histocompatibility complex 
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MS, mass spectrometry 
SILAC, stable isotope labeling amino acids in cell culture 
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Figure Legends 
Figure 1. Flow diagram of the approach to identify protein targets for modification by biotinylated 
amoxicillin. Briefly, cells are incubated in the presence of biotinylated amoxicillin, cells and conditioned 
medium are collected and analyzed by 2D-electrophoresis in duplicate gels. One gel is stained for total 
protein and its duplicate is transferred to nylon membranes and the blot incubated with horseradish-
peroxidase for detection of proteins bearing a biotin signal. Spots positive for biotin in the blot are 
matched to the protein spots in the gel, which are excised and analyzed by peptide fingerprinting. 
Figure 2. Competition or cooperation between protein modifications by drugs and electrophilic mediators 
or oxidants. Similarly to what has been described for endogenous electrophilic mediators, modification of 
proteins by drugs could have diverse consequences, of which several examples are presented. 1) If 
modification leads to protein unfolding, this can expose additional sites for modification in the protein. 2) 
Protein oxidation can increase or decrease its reactivity towards drugs. For instance, cysteine oxidation to 
sulfenic acid has been proposed to favor protein modification by sulfamethoxazole. 3) For some proteins, 
like GSTP1-1, there may be competition for among several modifications for the same residue. For 
instance, Cys47 has been shown to be modified by electrophilic prostaglandins, ethacrynic acid and 
chlorambucil, and a competition between these agents can be evidence in vitro. 4) Protein modification by 
oxidation can induce conformational alterations shielding reactive residues. See the text for a more 
detailed explanation. 
Figure 3. Formation of protein adducts with different drugs or their metabolites through covalent binding 
Figure 4. Potential role of drug-bearing exosomes in the intercellular transfer of haptenated proteins. In 
addition to classical pathways in which haptenated serum proteins can be taken up and processed by cells, 
we have observed that proteins can be haptenated intracellularly and be secreted either as soluble proteins 
or in extracellular vesicles. These vesicles can be taken up by other cells and therefore can constitute an 
additional vehicle for haptenated proteins. In addition, proteins already present in circulating exosomes 
from several cells could be haptenated, thus expanding the array of structures potentially involved in 
hypersensitivity responses. 
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Table 1. Some of the drug-adducts described. The residues modified are shown as well as whether they 
have been formed in patients (a) or under in vitro conditions (b). References correspond to: Meng, 2014 
[35]; Ariza, 2012 [62]; Hammond, 2014 [68]; Jenkins, 2009 [75]; Meng, 2013 [36]; Whitaker, 2011 [77]. 
Drug Target Protein Residues Modified Reference 
Abacavir HSA Lys159b, Lys190b, 
His146a, b, Cys34a, b 
Meng, 2014 
Amoxicillin HSA Lys190a, Lys195b Ariza, 2012 
Diclofenac HSA Lys195a, b, Lys199a, b Hammond, 
2014 
Flucloxacillin HSA Lys190a, b, Lys212a, b Jenkins, 2009 
Nevirapine HSA His146a, b, His242b,  
His338b, Cys34b 
Meng, 2013 
Piperacillin HSA Lys190a, b, Lys195a, b, 
Lys432a, b, Lys541a, b 
Whitaker, 2011 
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